▶ 調査レポート

世界のALK陽性肺がん治療市場 2021:企業別、地域別、種類・用途別

• 英文タイトル:Global ALK Positive Lung Cancer Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

GlobalInfoResearchが調査・発行した産業分析レポートです。世界のALK陽性肺がん治療市場 2021:企業別、地域別、種類・用途別 / Global ALK Positive Lung Cancer Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026 / GIR-107A13972資料のイメージです。• レポートコード:GIR-107A13972
• 出版社/出版日:GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(納期:2~3日)
• 産業分類:医療機器
• 販売価格(消費税別)
  Single User¥522,000 (USD3,480)▷ お問い合わせ
  Multi User¥783,000 (USD5,220)▷ お問い合わせ
  Corporate User¥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査資料では、ALK陽性肺がん治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ALK陽性肺がん治療の種類別市場規模(クリゾチニブ、アレクチニブ、セリチニブ、ブリガチニブ、その他)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・ALK陽性肺がん治療の市場概要
・企業情報(企業概要、製品概要、販売量、価格、売上):F. Hoffmann-La Roche、Pfizer、Novartis、TP Therapeutics、Bristol-Myers Squibb、Eli Lilly and Company、Takeda、Beacon Pharma
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年:クリゾチニブ、アレクチニブ、セリチニブ、ブリガチニブ、その他
・用途別分析2016年-2026年:病院、クリニック、その他
・ALK陽性肺がん治療の北米市場規模2016年-2026年:アメリカ、カナダ、メキシコ
・ALK陽性肺がん治療のヨーロッパ市場規模2016年-2026年:ドイツ、イギリス、フランス、ロシア、イタリア
・ALK陽性肺がん治療のアジア市場規模2016年-2026年:中国、日本、韓国、インド、東南アジア、オーストラリア
・ALK陽性肺がん治療の南米市場規模2016年-2026年:ブラジル、アルゼンチン
・ALK陽性肺がん治療の中東・アフリカ市場規模2016年-2026年:サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The ALK Positive Lung Cancer Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global ALK Positive Lung Cancer Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global ALK Positive Lung Cancer Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
ALK Positive Lung Cancer Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Crizotinib
Alectinib
Ceritinib
Brigatinib
Other

Market segment by Application, can be divided into
Hospital
Clinics
Other

Market segment by players, this report covers
F. Hoffmann-La Roche
Pfizer
Novartis
TP Therapeutics
Bristol-Myers Squibb
Eli Lilly and Company
Takeda
Beacon Pharma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of ALK Positive Lung Cancer Treatment
1.2 Classification of ALK Positive Lung Cancer Treatment by Type
1.2.1 Overview: Global ALK Positive Lung Cancer Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global ALK Positive Lung Cancer Treatment Revenue Market Share by Type in 2020
1.2.3 Crizotinib
1.2.4 Alectinib
1.2.5 Ceritinib
1.2.6 Brigatinib
1.2.7 Other
1.3 Global ALK Positive Lung Cancer Treatment Market by Application
1.3.1 Overview: Global ALK Positive Lung Cancer Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Other
1.4 Global ALK Positive Lung Cancer Treatment Market Size & Forecast
1.5 Global ALK Positive Lung Cancer Treatment Market Size and Forecast by Region
1.5.1 Global ALK Positive Lung Cancer Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global ALK Positive Lung Cancer Treatment Market Size by Region, (2016-2021)
1.5.3 North America ALK Positive Lung Cancer Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe ALK Positive Lung Cancer Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific ALK Positive Lung Cancer Treatment Market Size and Prospect (2016-2026)
1.5.6 South America ALK Positive Lung Cancer Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa ALK Positive Lung Cancer Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 ALK Positive Lung Cancer Treatment Market Drivers
1.6.2 ALK Positive Lung Cancer Treatment Market Restraints
1.6.3 ALK Positive Lung Cancer Treatment Trends Analysis
2 Company Profiles
2.1 F. Hoffmann-La Roche
2.1.1 F. Hoffmann-La Roche Details
2.1.2 F. Hoffmann-La Roche Major Business
2.1.3 F. Hoffmann-La Roche ALK Positive Lung Cancer Treatment Product and Solutions
2.1.4 F. Hoffmann-La Roche ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer ALK Positive Lung Cancer Treatment Product and Solutions
2.2.4 Pfizer ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis ALK Positive Lung Cancer Treatment Product and Solutions
2.3.4 Novartis ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Novartis Recent Developments and Future Plans
2.4 TP Therapeutics
2.4.1 TP Therapeutics Details
2.4.2 TP Therapeutics Major Business
2.4.3 TP Therapeutics ALK Positive Lung Cancer Treatment Product and Solutions
2.4.4 TP Therapeutics ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 TP Therapeutics Recent Developments and Future Plans
2.5 Bristol-Myers Squibb
2.5.1 Bristol-Myers Squibb Details
2.5.2 Bristol-Myers Squibb Major Business
2.5.3 Bristol-Myers Squibb ALK Positive Lung Cancer Treatment Product and Solutions
2.5.4 Bristol-Myers Squibb ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company ALK Positive Lung Cancer Treatment Product and Solutions
2.6.4 Eli Lilly and Company ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Eli Lilly and Company Recent Developments and Future Plans
2.7 Takeda
2.7.1 Takeda Details
2.7.2 Takeda Major Business
2.7.3 Takeda ALK Positive Lung Cancer Treatment Product and Solutions
2.7.4 Takeda ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Takeda Recent Developments and Future Plans
2.8 Beacon Pharma
2.8.1 Beacon Pharma Details
2.8.2 Beacon Pharma Major Business
2.8.3 Beacon Pharma ALK Positive Lung Cancer Treatment Product and Solutions
2.8.4 Beacon Pharma ALK Positive Lung Cancer Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Beacon Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global ALK Positive Lung Cancer Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 ALK Positive Lung Cancer Treatment Players Market Share
3.2.2 Top 10 ALK Positive Lung Cancer Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 ALK Positive Lung Cancer Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global ALK Positive Lung Cancer Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global ALK Positive Lung Cancer Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global ALK Positive Lung Cancer Treatment Revenue Market Share by Application (2016-2021)
5.2 ALK Positive Lung Cancer Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America ALK Positive Lung Cancer Treatment Revenue by Type (2016-2026)
6.2 North America ALK Positive Lung Cancer Treatment Revenue by Application (2016-2026)
6.3 North America ALK Positive Lung Cancer Treatment Market Size by Country
6.3.1 North America ALK Positive Lung Cancer Treatment Revenue by Country (2016-2026)
6.3.2 United States ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe ALK Positive Lung Cancer Treatment Revenue by Type (2016-2026)
7.2 Europe ALK Positive Lung Cancer Treatment Revenue by Application (2016-2026)
7.3 Europe ALK Positive Lung Cancer Treatment Market Size by Country
7.3.1 Europe ALK Positive Lung Cancer Treatment Revenue by Country (2016-2026)
7.3.2 Germany ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
7.3.3 France ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific ALK Positive Lung Cancer Treatment Market Size by Region
8.3.1 Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Region (2016-2026)
8.3.2 China ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8.3.5 India ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America ALK Positive Lung Cancer Treatment Revenue by Type (2016-2026)
9.2 South America ALK Positive Lung Cancer Treatment Revenue by Application (2016-2026)
9.3 South America ALK Positive Lung Cancer Treatment Market Size by Country
9.3.1 South America ALK Positive Lung Cancer Treatment Revenue by Country (2016-2026)
9.3.2 Brazil ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa ALK Positive Lung Cancer Treatment Market Size by Country
10.3.1 Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Country (2016-2026)
10.3.2 Turkey ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE ALK Positive Lung Cancer Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global ALK Positive Lung Cancer Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global ALK Positive Lung Cancer Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market ALK Positive Lung Cancer Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global ALK Positive Lung Cancer Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global ALK Positive Lung Cancer Treatment Revenue Market Share by Region (2021-2026)
Table 6. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 7. F. Hoffmann-La Roche Major Business
Table 8. F. Hoffmann-La Roche ALK Positive Lung Cancer Treatment Product and Solutions
Table 9. F. Hoffmann-La Roche ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer ALK Positive Lung Cancer Treatment Product and Solutions
Table 13. Pfizer ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis ALK Positive Lung Cancer Treatment Product and Solutions
Table 17. Novartis ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. TP Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. TP Therapeutics Major Business
Table 20. TP Therapeutics ALK Positive Lung Cancer Treatment Product and Solutions
Table 21. TP Therapeutics ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 23. Bristol-Myers Squibb Major Business
Table 24. Bristol-Myers Squibb ALK Positive Lung Cancer Treatment Product and Solutions
Table 25. Bristol-Myers Squibb ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 27. Eli Lilly and Company Major Business
Table 28. Eli Lilly and Company ALK Positive Lung Cancer Treatment Product and Solutions
Table 29. Eli Lilly and Company ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Takeda Corporate Information, Head Office, and Major Competitors
Table 31. Takeda Major Business
Table 32. Takeda ALK Positive Lung Cancer Treatment Product and Solutions
Table 33. Takeda ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Beacon Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Beacon Pharma Major Business
Table 36. Beacon Pharma ALK Positive Lung Cancer Treatment Product and Solutions
Table 37. Beacon Pharma ALK Positive Lung Cancer Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global ALK Positive Lung Cancer Treatment Revenue (USD Million) by Players (2019-2021)
Table 39. Global ALK Positive Lung Cancer Treatment Revenue Share by Players (2019-2021)
Table 40. Breakdown of ALK Positive Lung Cancer Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. ALK Positive Lung Cancer Treatment Players Head Office, Products and Services Provided
Table 42. ALK Positive Lung Cancer Treatment Mergers & Acquisitions in the Past Five Years
Table 43. ALK Positive Lung Cancer Treatment New Entrants and Expansion Plans
Table 44. Global ALK Positive Lung Cancer Treatment Revenue (USD Million) by Type (2016-2021)
Table 45. Global ALK Positive Lung Cancer Treatment Revenue Share by Type (2016-2021)
Table 46. Global ALK Positive Lung Cancer Treatment Revenue Forecast by Type (2021-2026)
Table 47. Global ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021)
Table 48. Global ALK Positive Lung Cancer Treatment Revenue Forecast by Application (2021-2026)
Table 49. North America ALK Positive Lung Cancer Treatment Revenue by Type (2016-2021) & (USD Million)
Table 50. North America ALK Positive Lung Cancer Treatment Revenue by Type (2021-2026) & (USD Million)
Table 51. North America ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021) & (USD Million)
Table 52. North America ALK Positive Lung Cancer Treatment Revenue by Application (2021-2026) & (USD Million)
Table 53. North America ALK Positive Lung Cancer Treatment Revenue by Country (2016-2021) & (USD Million)
Table 54. North America ALK Positive Lung Cancer Treatment Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe ALK Positive Lung Cancer Treatment Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe ALK Positive Lung Cancer Treatment Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe ALK Positive Lung Cancer Treatment Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe ALK Positive Lung Cancer Treatment Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe ALK Positive Lung Cancer Treatment Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue by Region (2021-2026) & (USD Million)
Table 67. South America ALK Positive Lung Cancer Treatment Revenue by Type (2016-2021) & (USD Million)
Table 68. South America ALK Positive Lung Cancer Treatment Revenue by Type (2021-2026) & (USD Million)
Table 69. South America ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021) & (USD Million)
Table 70. South America ALK Positive Lung Cancer Treatment Revenue by Application (2021-2026) & (USD Million)
Table 71. South America ALK Positive Lung Cancer Treatment Revenue by Country (2016-2021) & (USD Million)
Table 72. South America ALK Positive Lung Cancer Treatment Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa ALK Positive Lung Cancer Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. ALK Positive Lung Cancer Treatment Picture
Figure 2. Global ALK Positive Lung Cancer Treatment Revenue Market Share by Type in 2020
Figure 3. Crizotinib
Figure 4. Alectinib
Figure 5. Ceritinib
Figure 6. Brigatinib
Figure 7. Other
Figure 8. ALK Positive Lung Cancer Treatment Revenue Market Share by Application in 2020
Figure 9. Hospital Picture
Figure 10. Clinics Picture
Figure 11. Other Picture
Figure 12. Global ALK Positive Lung Cancer Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global ALK Positive Lung Cancer Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global ALK Positive Lung Cancer Treatment Revenue Market Share by Region (2016-2026)
Figure 15. Global ALK Positive Lung Cancer Treatment Revenue Market Share by Region in 2020
Figure 16. North America ALK Positive Lung Cancer Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe ALK Positive Lung Cancer Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America ALK Positive Lung Cancer Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa ALK Positive Lung Cancer Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. ALK Positive Lung Cancer Treatment Market Drivers
Figure 22. ALK Positive Lung Cancer Treatment Market Restraints
Figure 23. ALK Positive Lung Cancer Treatment Market Trends
Figure 24. F. Hoffmann-La Roche Recent Developments and Future Plans
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. TP Therapeutics Recent Developments and Future Plans
Figure 28. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 29. Eli Lilly and Company Recent Developments and Future Plans
Figure 30. Takeda Recent Developments and Future Plans
Figure 31. Beacon Pharma Recent Developments and Future Plans
Figure 32. Global ALK Positive Lung Cancer Treatment Revenue Share by Players in 2020
Figure 33. ALK Positive Lung Cancer Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 34. Global Top 3 Players ALK Positive Lung Cancer Treatment Revenue Market Share in 2020
Figure 35. Global Top 10 Players ALK Positive Lung Cancer Treatment Revenue Market Share in 2020
Figure 36. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 37. Global ALK Positive Lung Cancer Treatment Revenue Share by Type in 2020
Figure 38. Global ALK Positive Lung Cancer Treatment Market Share Forecast by Type (2021-2026)
Figure 39. Global ALK Positive Lung Cancer Treatment Revenue Share by Application in 2020
Figure 40. Global ALK Positive Lung Cancer Treatment Market Share Forecast by Application (2021-2026)
Figure 41. North America ALK Positive Lung Cancer Treatment Sales Market Share by Type (2016-2026)
Figure 42. North America ALK Positive Lung Cancer Treatment Sales Market Share by Application (2016-2026)
Figure 43. North America ALK Positive Lung Cancer Treatment Revenue Market Share by Country (2016-2026)
Figure 44. United States ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe ALK Positive Lung Cancer Treatment Sales Market Share by Type (2016-2026)
Figure 48. Europe ALK Positive Lung Cancer Treatment Sales Market Share by Application (2016-2026)
Figure 49. Europe ALK Positive Lung Cancer Treatment Revenue Market Share by Country (2016-2026)
Figure 50. Germany ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific ALK Positive Lung Cancer Treatment Sales Market Share by Type (2016-2026)
Figure 56. Asia-Pacific ALK Positive Lung Cancer Treatment Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific ALK Positive Lung Cancer Treatment Revenue Market Share by Region (2016-2026)
Figure 58. China ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. South Korea ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America ALK Positive Lung Cancer Treatment Sales Market Share by Type (2016-2026)
Figure 65. South America ALK Positive Lung Cancer Treatment Sales Market Share by Application (2016-2026)
Figure 66. South America ALK Positive Lung Cancer Treatment Revenue Market Share by Country (2016-2026)
Figure 67. Brazil ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East and Africa ALK Positive Lung Cancer Treatment Sales Market Share by Type (2016-2026)
Figure 70. Middle East and Africa ALK Positive Lung Cancer Treatment Sales Market Share by Application (2016-2026)
Figure 71. Middle East and Africa ALK Positive Lung Cancer Treatment Revenue Market Share by Country (2016-2026)
Figure 72. Turkey ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Saudi Arabia ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. UAE ALK Positive Lung Cancer Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Methodology
Figure 76. Research Process and Data Source